These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 2967738)

  • 1. Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
    Wils JA
    Chemioterapia; 1988 Feb; 7(1):60-2. PubMed ID: 2967738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
    Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical investigation of oral high-dose medroxyprogesterone acetate (MPA) in advanced breast cancer--double-blind controlled study: Japanese Group for MPA Treatment of Breast Cancer].
    Izuo M; Tominaga T; Yoshida M; Nomura Y; Abe O; Enomoto K; Kubo K; Takatani O
    Gan No Rinsho; 1985 May; 31(5):487-93. PubMed ID: 3160869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The protective effect of medroxyprogesterone acetate in patients with ovarian cancer treated with chemotherapy].
    Enzelsberger H; Sevelda P; Salzer H
    Gynakol Rundsch; 1988; 28 Suppl 2():195-7. PubMed ID: 2976722
    [No Abstract]   [Full Text] [Related]  

  • 5. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F; Martoni A; Piana E; Tomasi L; Grieco A; Farris A; Saccani F; Baroni M
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
    Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
    Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPA at high doses in advanced breast cancer: a statistical evaluation.
    Pannuti F; Camaggi CM; Strocchi E; Martoni A
    Chemioterapia; 1986 Jun; 5(3):159-63. PubMed ID: 2941172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer.
    Izuo M; Yoshida M; Tominaga T; Abe O; Enomoto K; Nomura Y; Kubo K; Takatani O
    Cancer; 1985 Dec; 56(11):2576-9. PubMed ID: 2932213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and laboratory evaluation of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer.
    Amadori D; Frassineti GL; Flamini E; Falcini F; Maltoni M; Nanni O; Riccobon A; Piccinini C
    Eur J Cancer; 1992; 28A(8-9):1331-4. PubMed ID: 1381210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medroxyprogesterone acetate (MPA) in the treatment of advanced breast cancer].
    Izuo M
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2604-11. PubMed ID: 2956928
    [No Abstract]   [Full Text] [Related]  

  • 15. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Metastatic breast cancer: a comparative study of the efficacy of tamoxifen and the sequential administration of tamoxifen and medroxyprogesterone acetate].
    Giralt E; Jouve M; Palangie T; Bretaudeau B; Asselain B; Magdelenat H; Merle S; Zajdela A; Pouillart P
    Bull Cancer; 1984; 71(1):22-9. PubMed ID: 6324934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
    Lorenz I; Mechl Z
    Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MPA plasma levels after oral administration in gastrectomized cancer patients during chemotherapy.
    Fornasiero A; Daniele O; Fosser V; Morandi P; Fiorentino MV
    Chemioterapia; 1985 Jun; 4(3):256-9. PubMed ID: 3161644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer].
    Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.